Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals expects 2025 net sales to exceed $1 billion, in line with prior guidance

Neutral Impact 2 of 5 guidance Written later

At the J.P. Morgan Healthcare Conference on January 13, 2026, Acadia Pharmaceuticals said it anticipates 2025 net sales will exceed $1 billion, consistent with its prior guidance. The company also posted a corporate slide presentation on its investor website.

Key points

  • Acadia anticipates 2025 net sales will exceed $1 billion.
  • The $1 billion figure is consistent with the company's prior guidance; the filing gives no new figures.
  • The information was presented at the J.P. Morgan Healthcare Conference on January 13, 2026, and a slide presentation was posted at ir.acadia.com.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECJan 13, 2026, 3:58 PM ET
Accession number0001193125-26-011706

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.